Search

Search Constraints

You searched for: Author/Creator Rosati, G.

Search Results

1. LBA23FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. (18th September 2017)

3. 2357 Prognostic factors in 709 advanced gastric cancer patients exposed to second-line therapy. (September 2015)

4. 2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with "non diffusive type" gastric carcinoma radically resected. (September 2015)

6. Mercury in the Black Sea: New Insights From Measurements and Numerical Modeling. Issue 4 (13th April 2018)

7. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. (May 2021)

8. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. Issue 4 (July 2016)

10. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015)